摘要
目的探讨瑞戈非尼联合信迪利单抗治疗复发肝癌患者的临床疗效。方法选择2019年2月至2022年12月河南省人民医院收治的98例复发肝癌患者为研究对象,按照随机数字表法分为对照组与观察组,每组49例。对照组在对症支持治疗的基础上给予瑞戈非尼治疗,观察组在对照组的基础上给予信迪利单抗治疗。比较两组临床疗效、免疫功能[分化簇(CD)3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)比值]、血清肿瘤标志物[甲胎蛋白(AFP)、磷脂酰肌醇蛋白聚糖-3(GPC3)]及不良反应。结果观察组客观缓解率和疾病控制率均明显高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)比值均显著高于对照组,CD8^(+)显著低于对照组,血清AFP、GPC3水平均显著低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异未见统计学意义(P>0.05)。结论瑞戈非尼联合信迪利单抗治疗复发肝癌可提高临床疗效,提高机体免疫力,降低血清中肿瘤标志物水平。
Objective To investigate the clinical efficacy of regorafenib combined with xindilizumab on patients with recurrent hepatocellular carcinoma(HCC).Methods From February 2019 to December 2022,98 patients with recurrent liver cancer were randomly divided into control group and observation group,with 49 cases in each group.The control group was given symptomatic and supportive treatment and regorafenib,and the observation group was given sindilizumab on the basis of the control group.The clinical efficacy,immune function[differentiation cluster(CD)3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)ratio],serum tumor markers[alpha-fetoprotein(AFPAFP),phosphatidylinositol proteoglycan-3(GPC3)]and adverse reactions were compared between the two groups.Results The objective response rate and disease control rate in the observation group were significantly higher than those in the control group,and the differences were significant(P<0.05).After treatment,the levels of CD3^(+),CD4^(+),and the ratio of CD4^(+)/CD8^(+)in the observation group were significantly higher than those in the control group,CD8^(+)was significantly lower than that in the control group,and the levels of serum AFP and GPC3 were significantly lower than those in the control group.The differences were significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Regorafenib combined with xindilizumab can improve the clinical efficacy,improve the immunity,reduce the serum tumor markers in patients with recurrent hepatocellular carcinoma.
作者
贾萌
徐健
贾江坤
余淼
申权
黄今朝
Jia Meng;Xu Jian;Jia Jiangkun;Yu Miao;Shen Quan;Huang Jinzhao(Department of Hepatobiliary Surgery,the People's Hospital of Henan,Zhengzhou 450003,China)
出处
《临床医学》
2025年第8期80-83,共4页
Clinical Medicine
关键词
瑞戈非尼
信迪利单抗
复发肝癌
临床疗效
Regorafenib
Xindilizumab
Recurrent hepatocellular carcinoma
Clinical efficacy
